

ASX RELEASE

2 November 2020

Notice Pursuant to ASX Listing Rule 3.11.2 – Change of Exercise Price of Options

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) wishes to advise that following completion of the 3 for 5 accelerated non-renounceable entitlement offer in early August 2020 the following changes to the exercise prices of its unlisted options have been affected in accordance with ASX Listing Rule 6.22.2:

Details of Options	New Exercise Price
Options Exercise Price \$0.15 Expiry Date 30 June 2022	\$0.14
Options Exercise Price \$0.60 Expiry Date 31 March 2022	\$0.59
Options Exercise Price \$0.60 Expiry Date 31 August 2022	\$0.59
Options Exercise Price \$0.60 Expiry Date 31 August 2023	\$0.59
Options Exercise Price \$0.165 Expiry Date 24 June 2024	\$0.155

In accordance with ASX Listing Rule 3.11.2 these changes are to become effective on Monday 7 November 2020.

Replacement holding statements and application forms for exercising options will be despatched to all optionholders.

This ASX announcement has been approved and authorised by the Board.

- End -

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company (ASX:ATX) advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer therapy and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF).

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com